GSK plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Lynn Baxter | b) Position/status President, Europe | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 6 (partnership shares) | £19.6290 6 (matching shares) | d) Aggregated information | Aggregated volume Price 12 Ordinary Shares £19.6290 | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Julie Brown | b) Position/status Chief Financial Officer | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 6 (partnership shares) | £19.6290 6 (matching shares) | d) Aggregated information | Aggregated volume Price 12 Ordinary Shares £19.6290 | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name James Ford | b) Position/status SVP and Group General Counsel, Legal and Compliance | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 6 (partnership shares) | £19.6290 6 (matching shares) | d) Aggregated information | Aggregated volume Price 12 Ordinary Shares £19.6290 | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name David Redfern | b) Position/status President, Corporate Development | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 6 (partnership shares) | £19.6290 6 (matching shares) | d) Aggregated information | Aggregated volume Price 12 Ordinary Shares £19.6290 | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Regis Simard | b) Position/status President, Global Supply Chain | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 6 (partnership shares) | £19.6290 6 (matching shares) | d) Aggregated information | Aggregated volume Price 12 Ordinary Shares £19.6290 | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Philip Thomson | b) Position/status President, Global Affairs | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 6 (partnership shares) | £19.6290 6 (matching shares) | d) Aggregated information | Aggregated volume Price 12 Ordinary Shares £19.6290 | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Deborah Waterhouse | b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 6 (partnership shares) | £19.6290 6 (matching shares) | d) Aggregated information | Aggregated volume Price 12 Ordinary Shares £19.6290 | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Victoria Whyte | b) Position/status SVP & Company Secretary | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 7 (partnership shares) | £19.6290 7 (matching shares) | d) Aggregated information | Aggregated volume Price 14 Ordinary Shares £19.6290 | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Neil Falkingham | b) Position/status PCA of Lynn Baxter (President, Europe) | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 6 (partnership shares) | £19.6290 6 (matching shares) | d) Aggregated information | Aggregated volume Price 12 Ordinary Shares £19.6290 | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Luke Miels | b) Position/status Chief Executive Officer | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 3 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Lynn Baxter | b) Position/status President, Europe | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 34 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name James Ford | b) Position/status SVP and Group General Counsel, Legal and Compliance | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 11 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name David Redfern | b) Position/status President Corporate Development | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 70 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Regis Simard | b) Position/status President, Global Supply Chain | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 28 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Philip Thomson | b) Position/status President, Global Affairs | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 45 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Deborah Waterhouse | b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 58 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Victoria Whyte | b) Position/status SVP & Company Secretary | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 54 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Neil Falkingham | b) Position/status PCA of Lynn Baxter (President, Europe) | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 on shares held through the Company's Share Reward Plan | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6290 57 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Victoria Whyte | b) Position/status SVP & Company Secretary | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6297 216 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
1. Details of PDMR/person closely associated with them ('PCA') | a) Name Iain Whyte | b) Position/status PCA of Victoria Whyte (SVP & Company Secretary) | c) Initial notification/ amendment Initial notification | 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | a) Name GSK plc | b) LEI 5493000HZTVUYLO1D793 | 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2026 | c) Price(s) and volume(s) Price(s) Volume(s) | £19.6297 1,050 | d) Aggregated information N/A (single transaction) | Aggregated volume Price | e) Date of the transaction 2026-07-09 | f) Place of the transaction London Stock Exchange (XLON) |
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHSFIFDDEMSEFW